Vemurafenib: a guide to its use in unresectable or metastatic melanoma.

Abstract

Oral vemurafenib (Zelboraf(®)) is a first-in-class, small molecule BRAF(V600E) inhibitor indicated for the treatment of unresectable or metastatic melanoma in BRAF(V600) mutation-positive patients (EU) or BRAF(V600E) mutation-positive patients (USA). Compared with intravenous dacarbazine, vemurafenib significantly improved overall survival and progression-free survival in patients with unresectable, previously untreated, BRAF(V600E) mutation-positive, stage IIIC or IV melanoma. Oral vemurafenib was generally well tolerated, with cutaneous adverse events among the most commonly occurring adverse events.

• Authors: Gillian M Keating, Katherine A Lyseng-Williamson
• Journal: American journal of clinical dermatology (Am J Clin Dermatol) Vol. 14 Issue 1 Pg. 65-9 (Feb 2013) ISSN: 1179-1888 [Electronic] New Zealand
• PMID: 23329082 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Indoles
• Sulfonamides
• Vemurafenib
• BRAF protein, human
• Proto-Oncogene Proteins B-raf

Topics

• Administration, Oral
• Antineoplastic Agents (adverse effects, pharmacology, therapeutic use)
• Disease-Free Survival
• Humans
• Indoles (adverse effects, therapeutic use)
• Melanoma (drug therapy, pathology)
• Mutation
• Neoplasm Metastasis
• Neoplasm Staging
• Proto-Oncogene Proteins B-raf (antagonists & inhibitors, genetics)
• Skin Neoplasms (drug therapy, pathology)
• Sulfonamides (adverse effects, therapeutic use)
• Survival Rate
• Vemurafenib